score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline	Guideline		Copy Number	AR	Amplification				0.0	0.0		Putatively Actionable	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf	Putatively Actionable	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor activation is a potential mechanism of recurrence of prostate cancer during androgen deprivation therapy.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf						0				AR Amplification		PROS12319B-SU2C-06115115	PROS12319B-SU2C-06115115-Tumor-SM-4W2NA	
Putatively Actionable		Preclinical		Copy Number	KEAP1	Deletion				0.0	0.0									Putatively Actionable	Radiation therapy	Radiation	Radiation therapy	In a mouse model of lung scamous cell carcinoma, deletion of KEAP1 promoted tumor aggressiveness, metastasis, and resistance to oxidative stress and radiotherapy (RT). KEAP1 / NRF2 mutation status predicted risk of local recurrence after RT in patients with non-small lung cancer (NSCLC).	Jeong Y, Hoang NT, Lovejoy A, et al. Role of / and Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance Cancer Discov. 2017; 7(1):86-101.	https://doi.org/10.1158/2159-8290.cd-16-0127						0				KEAP1 Deletion		PROS12319B-SU2C-06115115	PROS12319B-SU2C-06115115-Tumor-SM-4W2NA	
Investigate Actionability	Preclinical		Clinical evidence	Rearrangement	TMPRSS2	Fusion	TMPRSS2--ETV4			0.0	0.0		Investigate Actionability	Rucaparib	PARP inhibition	Targeted therapy	Cells which harbored the TMPRSS2-ERG fusion became radiosensitive following radiation and PARP inhibitor, specifically Rucaparib.	Chatterjee P, Choudhary GS, Sharma A, et al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS ONE. 2013;8(4):e60408.	https://doi.org/10.1371/journal.pone.0060408								Investigate Actionability	0.0	A cohort of men with localized prostate cancer was followed and a statistically significant association between the presense of the TMPRSS2-ERG fusion and prostate cancer specific death was observed. Prostate cancer with this fusion may be of a more aggressive phenotype.	Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26(31):4596-9.	https://doi.org/10.1038/sj.onc.1210237	0				TMPRSS2--ETV4 Fusion	0.0	PROS12319B-SU2C-06115115		
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						PROS12319B-SU2C-06115115		
Investigate Actionability	Preclinical			Copy Number	FGFR1	Deletion				0.0	0.0		Investigate Actionability	Infigratinib	FGFR inhibition	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.	https://doi.org/10.1158/2159-8290.CD-12-0210													0				FGFR1 Deletion		PROS12319B-SU2C-06115115	PROS12319B-SU2C-06115115-Tumor-SM-4W2NA	
Biologically Relevant				Copy Number	MC1R	Deletion				0.0	0.0																					0				MC1R Deletion		PROS12319B-SU2C-06115115	PROS12319B-SU2C-06115115-Tumor-SM-4W2NA	
Biologically Relevant				Microsatellite Stability	Supporting variants		ACVR2A p.K435fs (Frameshift), PRDM2 p.703_704insP (Insertion), MSH3 p.63_64insAAP (Insertion)																									0				Supporting variants: ACVR2A p.K435fs (Frameshift), PRDM2 p.703_704insP (Insertion), MSH3 p.63_64insAAP (Insertion)		PROS12319B-SU2C-06115115		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.661																									0				COSMIC Signature (version 2) 1 (66%)		PROS12319B-SU2C-06115115		
Biologically Relevant				Mutational Signature	COSMIC Signature 15	version 2	0.261																									0				COSMIC Signature (version 2) 15 (26%)		PROS12319B-SU2C-06115115		
